- Home
- DATS vs MTVA Comparison
DATS vs MTVA Comparison
Compare DATS & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- MTVA
- Stock Information
- Founded
- DATS 2014
- MTVA 2014
- Country
- DATS United States
- MTVA United States
- Employees
- DATS N/A
- MTVA N/A
- Industry
- DATS Computer Software: Prepackaged Software
- MTVA
- Sector
- DATS Technology
- MTVA
- Exchange
- DATS Nasdaq
- MTVA NYSE
- Market Cap
- DATS 13.4M
- MTVA 14.3M
- IPO Year
- DATS 2021
- MTVA N/A
- Fundamental
- Price
- DATS $2.60
- MTVA $0.67
- Analyst Decision
- DATS
- MTVA Strong Buy
- Analyst Count
- DATS 0
- MTVA 2
- Target Price
- DATS N/A
- MTVA $7.50
- AVG Volume (30 Days)
- DATS 375.4K
- MTVA 121.8K
- Earning Date
- DATS 08-13-2025
- MTVA 08-13-2025
- Dividend Yield
- DATS N/A
- MTVA N/A
- EPS Growth
- DATS N/A
- MTVA N/A
- EPS
- DATS N/A
- MTVA N/A
- Revenue
- DATS $388.00
- MTVA N/A
- Revenue This Year
- DATS N/A
- MTVA N/A
- Revenue Next Year
- DATS N/A
- MTVA N/A
- P/E Ratio
- DATS N/A
- MTVA N/A
- Revenue Growth
- DATS N/A
- MTVA N/A
- 52 Week Low
- DATS $1.04
- MTVA $0.63
- 52 Week High
- DATS $9.34
- MTVA $5.16
- Technical
- Relative Strength Index (RSI)
- DATS 49.04
- MTVA N/A
- Support Level
- DATS $2.40
- MTVA N/A
- Resistance Level
- DATS $2.80
- MTVA N/A
- Average True Range (ATR)
- DATS 0.18
- MTVA 0.00
- MACD
- DATS -0.02
- MTVA 0.00
- Stochastic Oscillator
- DATS 33.64
- MTVA 0.00
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.